Targeting LIN28: a new hope in prostate cancer theranostics

Garima Shrivastava, Alaa Aa Aljabali, Seyed Hossein Shahcheraghi, Marzieh Lotfi, Madhur D Shastri, Shakti D Shukla, Dinesh K Chellappan, Niraj Kumar Jha, Krishnan Anand, Harish Dureja, Ritesh M Pabari, Vijay Mishra, Abdulmajeed G Almutary, Abdullah M Alnuqaydan, Nitin Charbe, Parteek Prasher, Poonam Negi, Rohit Goyal, Kamal Dua, Gaurav GuptaÁngel Serrano-aroca, Bojlul Bahar, Debmalya Barh, Pritam Kumar Panda, Kazuo Takayama, Kenneth Lundstorm, Paul Mccarron, Hamid Bakshi, Murtaza M Tambuwala

Research output: Contribution to journalSpecial issuepeer-review

8 Citations (Scopus)
24 Downloads (Pure)


The mortality and morbidity rates for prostate cancer have recently increased to alarming levels, rising higher than lung cancer. Due to a lack of drug targets and molecular probes, existing theranostic techniques are limited. Human LIN28A and its paralog LIN28B overexpression are associated with a number of tumors resulting in a remarkable increase in cancer aggression and poor prognoses. The current review aims to highlight recent work identifying the key roles of LIN28A and LIN28B in prostate cancer, and to instigate further preclinical and clinical research in this important area.
Original languageEnglish
Pages (from-to)3873-3880
Number of pages8
JournalFuture Oncology
Issue number29
Early online date15 Jul 2021
Publication statusPublished (in print/issue) - 31 Oct 2021

Bibliographical note

Publisher Copyright:
© 2021 Future Medicine Ltd.. All rights reserved.


  • Cancer
  • theranostic
  • Therapeutic
  • LIN28B
  • prostate cancer
  • LIN28A
  • Special Report
  • biomarker
  • Humans
  • Male
  • Molecular Targeted Therapy
  • RNA-Binding Proteins/metabolism
  • Prostatic Neoplasms/pathology
  • Precision Medicine


Dive into the research topics of 'Targeting LIN28: a new hope in prostate cancer theranostics'. Together they form a unique fingerprint.

Cite this